top of page
High-Grade NET Resources (Twitter Header).png

Resources for High-Grade Neuroendocrine Tumors & Neuroendocrine Carcinoma

Learn more about clinical trials specifically for High Grade, Grade 3 (G3) Neuroendocrine Tumor (NET) and Neuroendocrine Carcinoma (NEC).  

WATCH

LISTEN

Episode 48 - NCF Podcast.jpg

DLL3 is emerging as a promising new target for neuroendocrine cancers. In this episode, Dr. Rohit Thummalapalli, medical oncologist at Memorial Sloan Kettering Cancer Center, explains what DLL3 is, how it works, who might benefit, and what current clinical trials are teaching us. He breaks down the science, treatment options, and future directions in a way that is clear, approachable, and designed to help patients and families better understand this developing area of care.

Extrapulmonary neuroendocrine carcinoma (EP-NEC) is a rare and complex cancer that can be difficult to recognise, diagnose, and treat. This short video helps patients and care partners understand the disease, including what to expect from diagnosis and treatment, the urgency needed, and where support is available. It is designed to help patients and their families navigate this challenging condition. 

​

Click here for more information >>>

In this video podcast by COR2ED, Neuroendocrine Patient Advocate Susan Meckler-Plummer joins Medical Oncologist Dr. Aman Chauhan to discuss extra-pulmonary neuroendocrine carcinomas (EP-NECs).

 

Click here for more information >>>

Podcast Episode 25  Website.png

What are Grade 3 Poorly Differentiated Neuroendocrine Carcinoma (NEC)? What makes NEC unique? Can a NET transform to NEC? Dr. Nitya Raj from Memorial Sloan Kettering Cancer Center in New York City explains NEC tumor biology and how it guides treatment strategy. She also discusses current clinical trials and research.

2.png

What are grade 3 NETs and how is it different from grade 3 NEC and other types of NETs? Dr. Mohamad (Bassam) Sonbol from Mayo Clinic in Phoenix, Arizona, enlightens us on this fairly new entity, including treatment options, treatment sequencing and clinical trials.

PATIENT STORY

A patient living and thriving with high grade neuroendocrine cancer shares her inspiring story.

FACEBOOK GROUP

For more information & and support, contact high grade patient advocate Susan Meckler Plummer, who supported her late husband with NEC.

Susan Meckler Plummer

609-731-0322 

susan@netsmission.org

NEUROENDOCRINE CANCER FOUNDATION
 
Mailing Address:
PO BOX 370466
DENVER, CO 80237

info@ncf.net
​
  • Facebook
  • Instagram
  • X
  • Youtube
  • LinkedIn

© 2025 by Neuroendocrine Cancer Foundation

bottom of page